A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 305
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : HC2
Long Form : Hybrid Capture 2
No. Year Title Co-occurring Abbreviation
2019 Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population. HR, LR, NPV
2019 Detection of Cervical Neoplasia by Human Papillomavirus Testing in an Atypical Squamous Cells-Undetermined Significance Population: Results of the Becton Dickinson Onclarity Trial. ASCUS, CIN2, HPV
2019 Human papillomavirus DNA, HPV L1 capsid protein and p16INK4a protein as markers to predict cervical lesion progression. HPV, HR-HPV, TCT
2019 Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. AHPV, GAST
2019 Onclarity Human Papillomavirus Extended Genotyping in the Management of Cervical Intraepithelial Neoplasia 2+ Lesions. CIN, HPV
2018 Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework. HR
2018 Clinical Evaluation of INNO-LiPA HPV Genotyping EXTRA II Assay Using the VALGENT Framework. HR
2018 Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. AHPV, CIN, LBC
2018 Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women. CI, HPV, HR, RLU/CO
10  2018 Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review. HPV
11  2018 Development of a pilot proficiency program for human papillomavirus DNA detection. EQA, EQAP, HPV
12  2018 Feasibility study of a human papillomavirus E6 and E7 oncoprotein test for the diagnosis of cervical precancer and cancer. CIN, HPV, TCT
13  2018 High-risk HPV detection and associated cervical lesions in a population of French menopausal women. HR
14  2018 HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia. ---
15  2018 Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. CIR, HR-HPV, RLU/CO, VIA
16  2018 Impact of Acetic Acid on HPV Testing Using Hybrid Capture 2. AA, HPV, RLUs
17  2018 Impact of operational factors on HPV positivity rates in an HPV-based screening study in Colombia. ---
18  2018 Postmenopausal Squamous Atypia: Cytologic Features, Hybrid Capture 2 Tests and Contribution to the ASCUS Pool. ASCUS, PSA, RLU/CO, SIL
19  2018 Risk of high-risk human papillomavirus infection and cervical precancerous lesions with past or current trichomonas infection: a pooled analysis of 25,054 women in rural China. LBC, TV
20  2018 Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. HPV, LA
21  2018 [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status]. AGC, ASC-H, ASCUS, HPV, HSIL, MALDI-TOF, NILM
22  2017 Accuracy of triage strategies for human papillomavirus DNA-positive women in low-resource settings: A cross-sectional study in China. CIN, HPV, LRS, RLU/CO, VIA
23  2017 Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities. Amp, HR-HPV, LA
24  2017 Comparison of GeneFinder human papillomavirus (HPV) Liquid Beads Microarray PCR Kit and Hybrid Capture 2 Assay for Detection of HPV Infection. HPV, HR-HPV, RFMP
25  2017 Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection. CC, HPV
26  2017 Cytology versus HPV testing for cervical cancer screening in the general population. ASCUS, CC, CIN, FP, HPV, LBC, LSIL, QUADAS, TN, TP
27  2017 Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types. HPV, NTCC2
28  2017 E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population. CC, CIN, HPV, TCT
29  2017 Evaluation of Viral Load as a Triage Strategy With Primary High-Risk Human Papillomavirus Cervical Cancer Screening. HPV, RLU/CO
30  2017 High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. CIN1, HR-HPV, LBC, SPOCCS-I
31  2017 HPV Status and Its Correlation with BCL2, p21, p53, Rb, and Survivin Expression in Breast Cancer in a Chinese Population. HPV, hrHPVs
32  2017 Performance of the cobas HPV Test for the Triage of Atypical Squamous Cells of Undetermined Significance Cytology in Cervical Specimens Collected in SurePath. ASCUS, CI, HPV, STM
33  2017 Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV Assays in South African HIV-Infected Women. HPV, HR-HPV, HSIL
34  2017 Prevalence of Human Papillomavirus in Self-Taken Samples from Screening Nonattenders. CI, CSi, HPV
35  2017 Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China. CI, CIR, HPV, SPOCCS-I
36  2017 Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening. HPV
37  2017 Risk factors for genital human papillomavirus among men in Tanzania. HPV, OR
38  2017 Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions. HR-HPV, STIs
39  2017 Testing for high-risk HPV in cervical and tonsillar paraffin-embedded tissue using a cartridge-based assay. FFPE, LC
40  2017 Validity Parameters of the Human Papillomavirus Detection Test Hybrid Capture 2 With and Without Cytology After Laser Destruction and Large Loop Excision of the Transformation Zone Treatment of High-Grade Cervical Intraepithelial Neoplasia Lesions. CIN, LLETZ
41  2016 Cell Block Preparation versus Liquid-Based Thin-Layer Cervical Cytology: A Comparative Study Evaluating Human Papillomavirus Testing by Hybrid Capture-2/Cervista, in situ Hybridization and p16 Immunohistochemistry. CB, HPV, IHC, ISH
42  2016 Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 mRNA Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women. CI, CIN3, HPV, OR
43  2016 Clinical Significance of an HPV DNA Chip Test with Emphasis on HPV-16 and/or HPV-18 Detection in Korean Gynecological Patients. HPV, HR, HSILs, OR
44  2016 Comparison of DNA testing strategies in monitoring human papillomavirus infection prevalence through simulation. LA, PCR
45  2016 Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2. ---
46  2016 Differential Detection of Human Papillomavirus Genotypes and Cervical Intraepithelial Neoplasia by Four Commercial Assays. CIN, HPV
47  2016 Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women. AUC, CI, CIN2, HPV, HR-HPV
48  2016 High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand. HPV
49  2016 High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis. AGC, HR-HPV
50  2016 HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data. HPV
51  2016 Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above. ---
52  2016 Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study. ASCUS, CI, CIN, HPV, HR-HPV, LA, PPV
53  2016 Hybrid Capture 2 and cobas human papillomavirus assays perform similarly on SurePath samples from women with abnormalities. ASCUS, CIN, HPV
54  2016 Implications of semi-quantitative HPV viral load estimation by Hybrid capture 2 in colposcopy practice. HPV
55  2016 Prevalence of High-Risk Human Papillomavirus Infection in China:  Analysis of 671,163 Human Papillomavirus Test Results From China's Largest College of American Pathologists-Certified Laboratory. HPV, MPFT
56  2016 Significance of "Not Detected but Amplified" Results by Real-Time PCR Method for HPV DNA Detection. Ct, HPV
57  2016 TMEM45A, SERPINB5 and p16INK4A transcript levels are predictive for development of high-grade cervical lesions. HPV
58  2016 Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer. ASC-H, CI, HR-HPV
59  2016 Xpert human papillomavirus test is a promising cervical cancer screening test for HIV-seropositive women. CIN, HIV, HPV
60  2016 [Investigation of human papillomavirus prevalence in women in Eskisehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method]. ASCCP, CC, FDA, HPV, RT-PCR
61  2015 A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years. CI, HPV
62  2015 A novel highly sensitive and specific flow cytometry system for cervical cancer screening. CIN, CPIx, FCM, HPV, SCC
63  2015 A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. AIS, HPV, IQR
64  2015 Alcohol and Tobacco Increases Risk of High Risk HPV Infection in Head and Neck Cancer Patients: Study from North-East Region of India. HNCs, HPV, HR-HPV, NMPCR
65  2015 Application of HPV DNA Testing in Follow-up after Loop Electrosurgical Excision Procedures in Northern Thailand. HSIL, LEEP, LSIL
66  2015 Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population. HPV
67  2015 Clinical performance of hybrid capture 2 human papillomavirus testing for recurrent high-grade cervical/vaginal intraepithelial neoplasm in patients with an ASC-US Papanicolaou test result during long-term posttherapy follow-up monitoring. ASCUS, CIN or VAIN, HPV
68  2015 Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study. CIN, HPV, LA
69  2015 Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus. CIN, HSIL
70  2015 Comparison of the performance of HPV tests in women with abnormal cytology: results of a study within the NHS cervical screening programme. CIN, HPV, RLU
71  2015 Evaluation of several screening approaches for detection of cervical lesions in rural Shandong, China. HR-HPV
72  2015 Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening. CIN, FTA card, HPV
73  2015 Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. AHPV, HPV, HR, LBC
74  2015 High prevalence of abnormal cervical smears in a hospital cohort of French women beyond the upper age limit screening program. CC, HR-HPV
75  2015 High prevalence of HPV59 in cytologically abnormal cervical samples. HPV, HR-HPV
76  2015 High-risk HPV platforms and test of cure: should specific HPV platforms more suited to screening in a 'test of cure' scenario be recommended? CIN, CSP, HR-HPV, LLETZ, TOC
77  2015 Histologic Outcomes in HPV-Positive and Cervical Cytology- Negative Women - Screening Results in Northern Thailand. AIS, HSIL, LBC
78  2015 HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. CCs, DFS, FIGO, HPV, OS, PCR
79  2015 Human Papillomavirus Infection Among 2460 Men in Denmark: Prevalence in Relation to Age Using 2 Human Papillomavirus DNA Testing Methods. CIs, HPV, PCR
80  2015 Human papillomavirus oncogenic mRNA testing for cervical cancer screening: baseline and longitudinal results from the CLEAR study. AHPV, CIN, HR-HPV
81  2015 Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey. AGC, ASC-H, ASCUS, CAP, HPV, HR
82  2015 Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. CI, HR-HPV
83  2015 Negative computer-imaged ThinPrep Pap test and positive hybrid capture2 HPV co-testing results: A quality assurance review. AIS, F/U, FOV, HSIL, NILM/RCC, QA, TPPT
84  2015 Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. ASC-US, ASCUS, HPV, LSILs, PALMS
85  2015 Relevance of HPV Screening for Triaging Equivocal Cytology Findings in the Pap II-p, Pap III and Pap IIID Groups - Results of Two Long-Term Studies. ---
86  2015 The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia. CI, HPV, HR, LA, RLB
87  2015 Value of PAX1 Methylation Analysis by MS-HRM in the Triage of Atypical Squamous Cells of Undetermined Significance. ASCUS, HPV, MS-HRM, PAX1
88  2015 [Association between CCND1 G870A polymorphism and radiotherapy response in high-risk human papillomavirus-related cervical cancer]. CCND1, HR-HPV, SNP
89  2015 [Early human papillomavirus testing predicts residual/recurrent disease after LEEP risk factors for predicting residual disease in high-grade squamous cervical intraepithelial neoplasia following LEEP conization]. CIN, HPV, LEEP, RLU
90  2015 [Effectiveness of FTA Elute indicating cartridge in combination with hybrid capture 2 for cervical cancer screening]. AUC
91  2014 A parallel study of careHPV and Hybrid Capture 2 human papillomavirus DNA testing for cervical cancer screening in rural China. TCM
92  2014 CCNA1 promoter methylation: a potential marker for grading Papanicolaou smear cervical squamous intraepithelial lesions. CCNA1
93  2014 Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening. HPV
94  2014 Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. ASCUS, HPV, LSIL, NCCSP
95  2014 Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results. HPV
96  2014 Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions. HR-HPV
97  2014 Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off. ---
98  2014 Comparison of digene hybrid capture 2, GeneMatrix PapilloScreen, and a PCR sequencing assay in detecting high-risk and probable high-risk oncogenic HPV genotypes in specimens from Korean women. HPV, HR, pHR
99  2014 Comparison of Hybrid Capture 2 Assay with Real-time-PCR for Detection and Quantitation of Hepatitis B Virus DNA. CHB, HBV, PCR
100  2014 Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection. HPV, HR